AG Schneider
Klinik für Allgemein-, Viszeral- und Kinderchirurgie
Ziel der Arbeitsgruppe ist es, die molekularen Ursachen von Vulnerabilitäten (Verletzlichkeiten) von gastrointestinalen Krebszellen (z.B. Pankreaskarzinom, Rektumkarzinom) zu verstehen, um neue und spezifische Therapien zu entwickeln. Dies soll prä-klinische und klinische Forschung verbinden, um letztendlich die Behandlung von Patient*innen mit gastrointestinalen Tumoren zu verbessern.
Projekte

- Epigenetische Regulatoren als therapeutische Zielstrukturen
- Onkogene Transkriptionsfaktoren
- Onkogene Signaltransduktion
- Medikamenten Screening und Entwicklung
- Primäre humane zelluläre Krebsmodelle
Mitglieder
Schwerpunktleiter Translationale Forschung

Kontaktinformationen
- Telefon: +49 551 3920488
- E-Mail-Adresse: guenter.schneider(at)med.uni-goettingen.de
PhD Studentin

Kontaktinformationen
- E-Mail-Adresse: carolindesiree.schneider(at)med.uni-goettingen.de
Publikationen 2022
- Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment
Falcomatà C, Bärthel S, Widholz SA, Schneeweis C, Montero JJ, Toska A, Mir J, Kaltenbacher T, Heetmeyer J, Swietlik JJ, Cheng JY, Teodorescu B, Reichert O, Schmitt C, Grabichler K, Coluccio A, Boniolo F, Veltkamp C, Zukowska M, Vargas AA, Paik WH, Jesinghaus M, Steiger K, Maresch R, Öllinger R, Ammon T, Baranov O, Robles MS, Rechenberger J, Kuster B, Meissner F, Reichert M, Flossdorf M, Rad R, Schmidt-Supprian M, Schneider G, Saur D. Nat Cancer. 2022 Jan 31. doi: 10.1038/s43018-021-00326-1. Epub ahead of print. PMID: 35122074. - NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer
Doffo J, Bamopoulos SA, Köse H, Orben F, Zang C, Pons M, den Dekker AT, Brouwer RWW, Baluapuri A, Habringer S, Reichert M, Illendula A, Krämer OH, Schick M, Wolf E, van IJcken WFJ, Esposito I, Keller U, Schneider G, Wirth M. Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):e2105691119. doi: 10.1073/pnas.2105691119. PMID: 35197278; PMCID: PMC8892327. - A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer
Lier S, Sellmer A, Orben F, Heinzlmeir S, Krauß L, Schneeweis C, Hassan Z, Schneider C, Patricia Gloria Schäfer A, Pongratz H, Engleitner T, Öllinger R, Kuisl A, Bassermann F, Schlag C, Kong B, Dove S, Kuster B, Rad R, Reichert M, Wirth M, Saur D, Mahboobi S, Schneider G. Bioorg Chem. 2022 Feb;119:105505. doi: 10.1016/j.bioorg.2021.105505. Epub 2021 Nov 20. PMID: 34838332. - HDAC2 facilitates metastasis of pancreatic cancer cells
Krauß L, Urban BC, Hastreiter S, Schneider C, Wenzel P, Hassan Z, Wirth M, Lankes K, Terrasi A, Klement C, Cernilogar FM, Öllinger R, de Andrade Krätzig N, Engleitner T, Schmid RM, Steiger K, Rad R, Krämer OH, Reichert M, Schotta G, Saur D, Schneider G. Pancreatic Cancer Metastasis. Cancer Res. 2022 Feb 15;82(4):695-707. doi: 10.1158/0008-5472.CAN-20-3209. PMID: 34903606. - Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems
Peschke K, Jakubowsky H, Schäfer A, Maurer C, Lange S, Orben F, Bernad R, Harder FN, Eiber M, Öllinger R, Steiger K, Schlitter M, Weichert W, Mayr U, Phillip V, Schlag C, Schmid RM, Braren RF, Kong B, Demir IE, Friess H, Rad R, Saur D, Schneider G, Reichert M. EMBO Mol Med. 2022 Feb 4:e14876. doi: 10.15252/emmm.202114876. Epub ahead of print. PMID: 35119792. - RelA is an essential target for enhancing cellular responses to the DNA repair/Ref-1 redox signaling protein and restoring perturbated cellular redox homeostasis in mouse PDAC cells
M. Mijit, R. Wireman, L. Armstrong, S. Gampala, Z. Hassan, C. Schneeweis, G. Schneider, M.L. Fishel, M.R. Kelley. Frontiers in Oncology (2022) accepted manuscript. - Targeting STAT3 Signaling Facilitates Responsiveness of Pancreatic Cancer Cells to Chemoradiotherapy
Flebbe H, Spitzner M, Marquet PE, Gaedcke J, Ghadimi BM, Rieken S, Schneider G, Koenig AO, Grade M. Cancers (Basel). 2022 Mar 3;14(5):1301. doi: 10.3390/cancers14051301. PMID: 35267609; PMCID: PMC8908974. - Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition
Schneeweis C, Hassan Z, Ascherl K, Wirth M, Koutsouli S, Orben F, Krauß L, Schneider C, Öllinger R, Krämer OH, Rad R, Reichert M, Robles MS, Saur D, Schneider G. Cancer Commun (Lond). 2022 Mar 7. doi: 10.1002/cac2.12280. Epub ahead of print. PMID: 35253411.
Publikationen 2021
- Genetic screens identify a context-specific PI3K/p27Kip1 node driving extrahepatic biliary cancer.
C. Falcomatà, S. Bärthel,…, G. Schneider*, Dieter Saur*. Cancer Discovery (2021) DOI: 10.1158/2159-8290.CD-21-0209 * equally contributing senior authors - Mesenchymal plasticity regulated by Prrx1 alters tumor differentiation, metastatic dissemination and response to chemotherapy in pancreatic cancer.
K. Feldmann,…, G. Schneider, D. Saur, M. Reichert. Gastroenterology (2021) 160(1):346-361.e24. - Important role of Nfkb2 in the KrasG12D-driven carcinogenesis in the pancreas.
Z. Hassan, C. Schneeweis, M. Wirth, S. Müller, C. Geismann, T. Neuß, K. Steiger, O.H. Krämer, R.M. Schmid, R. Rad, A. Arlt, M. Reichert, D. Saur, G. Schneider. Pancreatology (2021) 26:S1424-3903 - Impact of DNA repair and reactive oxygen species levels on radioresistance in pancreatic cancer.
L. Nguyen, S. Dobiasch, G. Schneider,…, S. E. Combs. Radiotherapy and Oncology (2021) 159:265-276. - Cannabidiol converts NFB into a tumor suppressor in glioblastoma with defined antioxidative properties.
M.N.M. Volmar,…, G. Schneider,…, R. Glass. Neuro-Oncology (2021) DOI: 10.1093/neuonc/noab095 - The SUMO Pathway in Pancreatic Cancer: Insights and Inhibition.
C. Schneeweis,…, , G. Schneider. British J. Cancer (2021) 124:531-538. - New insights into pancreatic cancer: notes from a virtual meeting.
E. Hessmann, G. Schneider. Gastroenterology (2021) 161(3):785-791. - Identification of cytokeratin24 as a tumor suppressor for the management of head and neck cancer.
D. Gül, N. Habtemichael, D. Dietrich, J. Dietrich, D. Goesswein, A. Khamis, E. Deuss, J. Künzel, G.Schneider, S. Strieth, R. Stauber. Biological Chemistry (2021) DOI: 10.1515/hsz-2021-0287. - Class 1 Histone Deacetylases and Ataxia-Telangiectasia Mutated Kinase Control the Survival of Pancreatic Cancer Cells upon dNTP Depletion. A. Nguyen, J. Murr, Y. Yen, G. Schneider, O.H. Krämer. Cells (2021) accepted manuscript.
- Inhibition of Wnt/β-catenin signaling sensitizes esophageal cancer cells to chemoradiotherapy.
M. Spitzner, G. Emons, K. Burkhard Schütz, H.A. Wolff, S. Rieken, M. Ghadimi, G.Schneider, M. Grade. International Journal of Molecular Sciences (2021) accepted manuscript. - Rationale for MYC Imaging and Targeting in Panceratic Cancer.
G. Schneider, M. Wirth, U. Keller, D. Saur. EJNMMI Research (2021) accepted manuscript.
Förderung
Das könnte Sie auch interessieren